Market Trends of Acne Therapeutics Industry
Retinoid Segment Expected to Hold a Significant Market Share Over the Forecast Period
The retinoid segment is expected to hold a significant share of the acne therapeutics market over the forecast period. Retinoid creams and gels are very effective at stopping or reducing mild to moderate acne, which has led to an increasing demand for retinoids, thereby contributing to the growth of the market. They can also be used as maintenance therapy to keep skin clear after successful treatment. Additionally, market players frequently launch novel and generic versions of retinoids to gain a competitive edge in the market. For instance, in February 2022, Stryke Club launched retinoid acne treatment with its Knockout Adapalene Gel that prevents pimples, blackheads, whiteheads, and clogged pores. The FDA-approved prescription-strength retinoid acne treatment is available without a prescription. The rising product launches for retinoid treatment will lead to increased adoption due to its benefits in treating acne, which is expected to drive the growth of this segment over the forecast period.
Furthermore, an increase in research and development for retired acne therapies will also contribute to the growth of this market over the forecast period. For instance, in October 2023, Bausch Health Companies Inc. received approval from the US Food and Drug Administration (FDA) for a New Drug Application for CABTREOTM (clindamycin phosphate, adapalene, and benzoyl peroxide) Topical Gel, indicated for the topical treatment of acne vulgaris. Such product approvals and increasing research around the combination of retinoids are expected to boost their sales and manufacturing, thereby boosting the segment’s growth.
Owing to the abovementioned factors, such as increasing product development and launches and increasing adoption of retinoids, the retinol segment is expected to register a significant share during the forecast period.
North America Expected to Continue Holding a Significant Market Share Over the Forecast Period
North America is expected to hold a notable share in the market over the forecast period owing to the increasing awareness among the population and the presence of major market players. The growing burden of acne in the region and recent product launches are also crucial factors driving the growth of the acne therapeutics market in North America. As per MDAcne’s data published in November 2023, 85% of people have experienced acne in some form at some point in their lives in the United States. The report also mentioned that 50 million people in the United States have acne of some kind. Similarly, the survey report published by the Canadian Skin Patient Alliance (CSPA) in September 2022 mentioned that 37% of the respondents in the survey reported having mild acne, 47% reported moderate acne, and 16% indicated severe acne in Canada in 2022.
Additionally, rising product approvals and product launches for acne treatment are also expected to drive the growth of this segment over the forecast period. For instance, in August 2022, Cutera received clearance from HealthCanada for the product AviClear for the treatment of mild, moderate, and severe acne and acne scars. Moreover, in September 2023, Sun Pharma Canada Inc. launched PRWINLEVI in Canada. WINLEVI is one of the first and only androgen receptor inhibitors indicated for the topical treatment of acne vulgaris (acne) in patients 12 years of age and older.
Moreover, in March 2022, Galderma launched TWYNEO Cream in the United States to treat facial acne at the American Academy of Dermatology’s Annual Meeting. The rising product launches in developed countries will lead to increased adoption, which is expected to drive growth across the North American market.
Thus, frequent product launches and product approvals for the development of novel acne therapies are expected to drive the North American market.
